NEWS
IMPAACT 2017, a study to evaluate the safety and pharmacokinetics of long-acting injectable cabotegravir and rilpivirine in children and adolescents living with HIV, is now enrolling.
NEWS
IMPAACT 2002, a multi-site cluster-randomized study of cognitive behavioral therapy and medication management for treatment of depression among youth living with HIV in the U.S., has closed to accrual.
News
IMPAACT 2009, a study of the PK, Feasibility, Acceptability, and Safety of Oral PrEP for Primary HIV Prevention during Pregnancy and Postpartum in Young Women and their Infants, is now enrolling
Read More
Abstracts Accepted
IMPAACT presented 16 abstracts at the 26th Conference on Retroviruses and Opportunistic Infections (CROI) held 4-7 March 2019.
See presented materials
Our mission
Our mission is to significantly decrease incident HIV and HIV-associated infections and to decrease mortality and morbidity due to HIV and HIV-associated infections and co-morbidities among infants, children, adolescents and pregnant/postpartum women.
This document highlights major steps in protocol implementation and gives a quick look at accrual for each study. It is updated monthly.
Proposals for new IMPAACT studies may be submitted by internal or external investigators in the form of a three-page study "capsule" any time.
Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.
